---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055610"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T08:34:45.697064+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics Q1 2024 net loss $135.6M ($1.33 loss per share); cash $634M; aficamten NDA on track for Q3 2024

## Summary
- Net loss of $135.6M ($1.33 per share) vs $131.3M loss ($1.38 per share) in Q1 2023.
- Cash and investments $634.3M as of March 31, 2024; revenue fell to $0.8M from $4.6M.
- Aficamten NDA submission planned for Q3 2024; MAA submission to EMA in Q4 2024.
- Initiated enrollment in pediatric HCM trial CEDAR-HCM; MAPLE-HCM enrollment expected to complete Q3 2024.
- Appointed Sung Lee as EVP, CFO effective May 8, 2024.

## SEC filing metadata
- accession: 0000950170-24-055610
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017024055610/0000950170-24-055610-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017024055610/cytk-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055610
- JSON: https://secwatch.observer/filing/0000950170-24-055610.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055610.txt

## Key facts
- Earnings Releases
  CYTOKINETICS INC reported first quarter of 2024 results: net income Net loss for the first quarter was $135.6 million, or $1.33 per share.
  - Period: first quarter of 2024
  - Net income: Net loss for the first quarter was $135.6 million, or $1.33 per share
  - Result: reported results
  source text: Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2024. Net loss for the first quarter was $135.6 million, or $1.33 per share, compared to net loss for the first quarter of 2023 of $131.3 million, or $1.38 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061983/000095017024055610/0000950170-24-055610-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.